OmniAb (OABI) Depreciation & Amortization (CF) (2022 - 2026)
OmniAb (OABI) reported Depreciation & Amortization (CF) of $606000.0 for Q1 2026, down 87.22% year-over-year from $4.7 million in Q1 2025, and down 92.14% quarter-over-quarter from $7.7 million in Q4 2025.
OmniAb (OABI) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $606000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $606000.0, down 87.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.6 million (down 24.64% YoY), and the FY2025 annual result was $21.8 million, down 7.76% from the prior year.
- Depreciation & Amortization (CF) retreated to $606000.0 in Q1 2026 per OABI's latest filing, from $7.7 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $7.7 million in Q4 2025 and troughed at $606000.0 in Q1 2026.
- A 5-year average of $4.9 million and a median of $4.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) jumped 54.15% in 2024, then slumped 87.22% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $4.8 million in 2022, then gained by 2.37% to $4.9 million in 2023, then soared by 54.15% to $7.6 million in 2024, then climbed by 1.33% to $7.7 million in 2025, then plunged by 92.14% to $606000.0 in 2026.
- Business Quant data shows OABI's Depreciation & Amortization (CF) at $606000.0 in Q1 2026, $7.7 million in Q4 2025, and $4.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 606,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 606,000.00 |
| Mar 31, 2026 | 606,000.00 |
| Dec 31, 2025 | 7.71 Mn |
| Dec 31, 2025 | 7.71 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 4.95 Mn |
| Mar 31, 2024 | 4.95 Mn |
| Dec 31, 2023 | 4.93 Mn |
| Dec 31, 2023 | 4.93 Mn |